The US Food and Drug Administration (FDA) has approved a non-opioid drug for severe post-surgical pain, which could “redefine ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

The previous pregnancy occurred 5 years before this pregnancy ... medium consistency and posterior, −3 station, vertex presentation, equivalent to a Bishop score of 3, with membranes intact.

At the time Nice said that it needed further detail about the effectiveness of the treatment, also known as exagamglogene autotemcel (exa-cel) and made by Vertex. It also needed ... a cure for people ...

Peripartum cardiac insufficiency (PPCM) is a rare but life-threatening condition that can affect previously heart-healthy women a few weeks before or after the birth of a child. For unknown reasons, ...

New York City Mayor Eric Adams is expected to meet with Director of Immigration and Customs Enforcement this week. As CBS ...

Researchers Find Improved Method for Treating Rare, Aggressive, Pregnancy-Related Cancer Feb. 5, 2025 — A new drug delivery system shows promise for treating a rare, aggressive form of cancer ...